Synlogic (NASDAQ: SYBX) has collaborated with Jim Collins and Tim Lu, pioneers in synthetic biology, to develop a platform for the design and advancement of therapeutic microbes. These microbes can function in a range of ways to treat diseases not easily addressable by systemically delivered, traditional therapies; and can adjust their activity based on environmental signals to deliver the right level of response where and when needed.

Headquarters Cambridge, MA
Twitter @synlogic_tx​
Pipeline Phase 1 clinical trials